What is your recommended adjuvant approach to resected NSCLC with both PD-L1>1% and EGFR mutation?
What would you do for a patient with a non-EGFR actionable mutation?
IMpower010 included EGFR and ALK mutated NSCLC. Is there any concern in the use of adjuvant immunotherapy for these patients?
Community PollStarted
How would you treat resected NSCLC with both PD-L1>1% and EGFR mutation?
87 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Virginia
Answered on
IMpower010 included patients with EGFR mutations, which made up about 10% of the patients enrolled in the trial. In the subgroup analysis of EGFR patients whose tumors expressed PDL1 ≥1%, the HR of 0.57 favored atezolizumab, but had a wide confidence interval (95% CI, 0.26-1.24). Other studies of im...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Case Comprehensive Cancer Center
Answered on
For patients with EGFR exon 19del and L858R mutations, I discuss the benefit in preventing disease recurrence by 3 years of osimertinib therapy following completion of adjuvant chemotherapy and I offer the treatment. I do not offer adjuvant atezolizumab to those patients.
Though patients with EGFR a...
Join for free or sign in to see the full answer